Page 30 - Libro de Ponencias Congres SEHH-SETH 2017

❯ Conclusiones
A pesar de no ser plenas, las asociaciones entre sig- nos citológicos de displasia y alteraciones genético- moleculares han permitido, y lo seguirán haciendo, estrechar el heterogéneo campo de los SMD, orien- tando la explicación de la patogénesis y contribuyen- do a la nomenclatura actual de estos síndromes. La ingente cantidad de datos procedente de la secuen- ciación del genoma sirven de apoyo ya, a la citología y a la citogenética, en la caracterización de los SMD. El desarrollo, en un futuro esperemos que cercano, de terapias dirigidas a estas alteraciones determinará, en nuestra opinión, que la biología molecular alcan- ce un papel principal en el diagnóstico de la mielo- displasia.
❯ Bibliografía
1. Rowley JD,Blaisdell RK JL.Chromosome studies in preleukemia.I.Aneuploidy of group C chromosomes in three patients. Blood. 27(6):782-99.
2. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Dis- tinct haematological disorder with deletion of long arm of No. 5 chromo- some. Nature. 1974;251(5474):437-8.
3. Boultwood J, Fidler C, Lewis S, Kelly S, Sheridan H, Littlewood TJ, et al. Molecu- lar Mapping of Uncharacteristically Small 5q Deletions in Two Patients with the 5q- Syndrome: Delineation of the Critical Region on 5q and Identi cation of a 5q- Breakpoint. Genomics. 1994;19(3):425-32.
4. Jerez A, Gondek LP, Jankowska AM, Makishima H, Przychodzen B, Tiu RV, et al.Topography,clinical,and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol. 2012;30(12):1343-9.
5. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identi cation of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-9.
6. Hahn CN,Chong CE,Carmichael CL,Wilkins EJ,Brautigan PJ,Li XC,et al.Heri- table GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43(10):1012-7.
7. Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, et al. Role of ca- sein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014;26(4):509-20.
8. Lai JL,Preudhomme C,Zandecki M,Flactif M,Vanrumbeke M,Lepelley P,et al. Myelodysplastic syndromes and acute myeloid-leukemia with 17p deletion - an entity characterized by speci c dysgranulopoiesis and a high-incidence of p53 mutations. Leukemia. 1995;9(3):370-81.
9. Grigg AP, Gascoyne RD, Phillips GL, Horsman DE. Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. Br J Haematol. 1993;83(1):158-65.
10. Gröschel S, Sanders MA, Hoogenboezem R, Zeilemaker A, Havermans M, Erpelinck C, et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling path- ways. Blood. 2015;125(1):133-9.
11. Dewald GW, Pierre R V, Phyliky RL. Three patients with structurally abnormal X chromosomes, each with Xq13 breakpoints and a history of idiopathic ac- quired sideroblastic anemia. Blood. 1982;59(1):100-5.
12. Yildirim E, Kirby JE, Brown DE, Mercier FE, Sadreyev RI, Scadden DT, et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell. 2013;152(4):727-42.
13. Felman P, Bryon PA, Gentilhomme O, Ffrench M, Charrin C, Espinouse D, Viala JJ. The syndrome of abnormal chromatin clumping in leucocytes: a myelo- dysplastic disorder with proliferative features? Br J Haematol. 70(1):49-54.
14. Cazzola M,Della Porta MG,Malcovati L.The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122(25):4021-34.
15. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classi cation of myeloid neo- plasms and acute leukemia. Blood. 2016;127(20):2391-405.
16. Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, et al. SF3B1 mutation identi es a distinct subset of myelodysplastic syn- drome with ring sideroblasts. Blood. 2015;126(2):233-41.
17. Visconte V, Avishai N, Mahfouz R, Tabarroki A, Cowen J, Sharghi-Moshtaghin R, et al. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. Leu- kemia. 2015;29(1):188-95.
18. Matsunawa M, Yamamoto R, Sanada M, Sato-Otsubo A, Shiozawa Y, Yoshida K, et al. Haploinsuf ciency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia. Leukemia. 2014;28(9):1844-50.
19. An J, González-Avalos E, Chawla A, Jeong M, López-Moyado IF, Li W, et al. Acute loss of TET function results in aggressive myeloid cancer in mice. Nat Commun. 2015;6:10071.
20. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013;45(8):942-6.
LIX Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia / Ponencias
30